Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4B | P0C869 | 8/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17775464 | 0.85 | ALOX15 (0.59) | PKMRECQLMEN1KMT2ATSHR | |
| SCHEMBL2858346 | 0.83 | PKM (0.63) | PKMRECQLMEN1KMT2ATSHR | |
| SCHEMBL4511288 | 0.82 | HTT (0.57) | PLA2G4BPKMRECQLMEN1KMT2A | |
| SCHEMBL2835976 | 0.82 | ALDH1A1 (0.61) | PLA2G4BPKMMEN1KMT2ASRD5A2 | |
| SCHEMBL171840 | 0.81 | MEN1 (0.61) | PKMRECQLMEN1KMT2ATSHR | |
| Hydrochloric Acid SCHEMBL10955756 | 0.81 | PKM (0.61) | PKMRECQLMEN1KMT2ATSHR | |
| SCHEMBL13916156 | 0.81 | KMT2A (0.54) | PKMRECQLMEN1KMT2AALDH1A1 | |
| SCHEMBL4427417 | 0.81 | PKM (0.54) | PKMRECQLMEN1KMT2AALDH1A1 | |
| SCHEMBL13168071 | 0.81 | SMN1; SMN2 (0.49) | PKMRECQLMEN1KMT2AALDH1A1 | |
| SCHEMBL6538992 | 0.81 | GAA (0.61) | PLA2G4BPKMKMT2AMAPK1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
| EP-0703216-B1 | Amidinophenol derivatives as protease inhibitors | ONO PHARMACEUTICAL CO (JP) | 1999-04-07 | — | — | EP | disclosed |
| EP-0703216-A1 | Amidinophenol derivatives as protease inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | PLA2G4B 690/4885PKM 2588/4885RECQL 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.